Profile and prevalence of aspirin resistance in patients with cardiovascular disease

American Journal of Cardiology

Volumn 88, Issue 3, 2001, Pages 230-235

  Gum, Patricia A ^a   Kottke Marchant, Kandice ^a   Poggio, Emilio D ^a   Gurm, Hitinder ^a   Welsh, Patricia A ^a   Brooks, Linda ^a   Sapp, Shelly K ^a   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADRENALIN; ARACHIDONIC ACID; COLLAGEN;

ADULT; AGE; AGED; ANALYZER; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; POLARIMETRY; PREDICTION; PRIORITY JOURNAL; RACE; SEX DIFFERENCE; SMOKING; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

ADULT; ASPIRIN; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PREVALENCE; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 0035421783     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01631-9     Document Type: Article

References (35)

1. One hundred years of aspirin
2. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
3. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
4. Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy
5. Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients
6. Development of aspirin resistance in persons with previous ischemic stroke
7. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina
8. Platelet aggregation studies in coronary artery disease. Effect of aspirin
9. Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically
10. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy
11. Sex difference in antithrombotic effect of aspirin
12. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients
13. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty
14. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin
15. PFA-100 system: A new method for assessment of platelet dysfunction
16. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients
17. Aspirin response and failure in cerebral infarction
18. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin
19. Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study
20. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting
21. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation
22. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy
23. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial
24. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs
25. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane
26. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance
27. Cyclooxygenases 1 and 2
28. Association of the platelet Pl(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bbeta 448 polymorphism with myocardial infarction and extent of coronary artery disease
29. Higher prevalence of GPIIIa PlA2 polymorphism in siblings of patients with premature coronary heart disease
30. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists
31. PlA Polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement
32. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement
33. PlA2 polymorphism and efficacy of aspirin
34. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment
35. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity